CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

Titre officiel

A Phase II Study of CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

Sommaire:

Le traitement habituel ou standard de cette maladie est l’administration d’une chimiothérapie pour ralentir la propagation de la maladie et soulager certains symptômes du cancer. Les patients auront déjà reçu au moins un traitement de chimiothérapie pour leur maladie à ce stade.

Description de l'essai

Primary Outcome:

• Objective Response defined by RECIST 1.1

Secondary Outcome:

• Disease Control Rate (DCR) defined by RECIST 1.1
• Number and severity of adverse events
• Molecular analyses of CFI-400945 on tumour cells through paired tumour biopsies using next generation DNA sequencing
• Molecular analyses of CFI-400945 on tumour cells through paired biopsies using immunohistochemistry

CFI-400945 is a new type of drug for breast cancer. Laboratory tests show that it works by blocking a specific protein called Polo-like Kinase 4 (PLK4) that is involved in cancer cell growth. CFI-400945 may slow down the growth of cancer cells or may cause cancer cells to die. This drug has been shown to shrink tumours in animals and has been studied in some patients and appears well tolerated with little side effects. CFI-400945 seems promising but it is not clear if it can offer better results than standard therapy.

Voir cet essai sur ClinicalTrials.gov